 Cue Biopharma, Inc. CUE, a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today it will present at the Jefferies Virtual Healthcare Conference 2020 on Thursday, June 4, 2020 at 9:00 a.m. EDT. Daniel Passeri, chief executive officer, will provide an overview of the Companys Immuno-STATTM Selective Targeting and Alteration of T cells and Neo-STATTM platforms and an update on the on-going clinical trial for its lead drug candidate CUE-101, as well as pipeline progress and anticipated corporate development milestones. The presentation will also be archived for 30 days on the Companys website. 